Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Depressive Disorder, Major
Interventions: Venlafaxine ER, Dialogues Time to Talk Program; Drug · Behavioral
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 537 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 44
States / cities: Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 39 more

Conditions: Older Adults, Anxiety, Depression, Major Surgical Resection of a Thoracic Malignancy, Major Surgical Resection of an Abdominal Malignancy
Interventions: Behavioral Activation, Medication Optimization, Usual care resources; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: DSP-1053, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Major Depressive Disorder, Partner Relational Disorder (V61.10)
Interventions: Weekly marital therapy, As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Physical Activity-based Interventions; Behavioral
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Late Life Depression (LLD), Depression - Major Depressive Disorder
Interventions: High-intensity (6 mA) transcranial direct current stimulation (tDCS); Device
Lead sponsor: Andre Russowsky Brunoni; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder, Healthy
Interventions: PET scan, Rolipram; Procedure · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depression, Late Life Depression (LLD)
Interventions: Not listed
Lead sponsor: University of Southern California; Other
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 2
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Schizophrenia, Bipolar Disorder, Major Depression
Interventions: Person-Centered Care, Measurement-Based Care; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2,443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Lebanon, New Hampshire • Pittsburgh, Pennsylvania

Conditions: Depression
Interventions: duloxetine, fluoxetine, citalopram, paroxetine, sertraline; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Carson, California • Irvine, California • San Diego, California + 58 more

Conditions: Mood Disorder, Bipolar Disorder, Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Depression
Interventions: Telephone-administered cognitive behavioral therapy (T-CBT), Face-to-face administered CBT (FtF-CBT); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 14 Years to 18 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Major Depressive Disorder (MDD)
Interventions: Cognitive therapy for depression; Behavioral
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Bryant, Arkansas • Anaheim, California • Orange, California + 15 more

Conditions: Seasonal Affective Disorder, Mood Disorders, Depression
Interventions: bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 25
States / cities: Scottsdale, Arizona • Encino, California • Los Alamitos, California + 21 more

Conditions: Major Depressive Disorder
Interventions: Azetukalner; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 69
States / cities: Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 58 more

Conditions: Insomnia
Interventions: Eszopiclone, Placebo, Escitalopram; Drug
Lead sponsor: Lehigh Center for Clinical Research; Other
Eligibility: 65 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Allentown, Pennsylvania

Conditions: Major Depressive Disorder (MDD), Cognitive Dysfunction
Interventions: Motivationally Enhanced Compensatory Cognitive Training for Major Depressive Disorder (ME-CCT-MDD), Goal-focused Supportive Contact; Behavioral
Lead sponsor: Portland VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Major Depressive Disorder
Interventions: Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder (MDD)
Interventions: Conversational AI system vs Usual Care; Other
Lead sponsor: George Mason University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Major Depressive Disorder
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Major Depressive Disorder
Interventions: High Dose Resistance Exercise Training, Low Dose Resistance Exercise Training Group; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Ames, Iowa • Madison, Wisconsin

Search by objective public record fields.

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

Behavioral Activation and Medication Optimization For Improving Perioperative Mental Health In Older Adults Undergoing Oncologic Surgery

A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder

Treatment of Mood and Marriage Study (TOMMS)

Trial of Surf and Hike Therapy for Major Depressive Disorder

tDCS for Late-Life Depression

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients

Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project

Person-Centered Versus Measurement-Based Care in Mental Health

A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression

Examination of Brain Serotonin Receptors in Patients With Mood Disorders

Effectiveness of Telephone Versus Face-to-Face CBT in Treating People With Depression

Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

Improving Depression Outcome by Enhancing Memory for Cognitive Therapy

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

An Open-Label Study of Azetukalner in Major Depressive Disorder

Eszopiclone Co-Administered With Escitalopram for Insomnia in Elderly Adults With Major Depressive Disorder

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home

Evaluating Conversational Artificial Intelligence for Depression Management

Phenotype Depression Study

RESISTance Exercise for Depression Trial